Clinical pharmacokinetics of aztreonam in cancer patients

P. G. Jones, G. P. Bodey, E. A. Swabb, D. H. Ho, V. Fainstein, J. Pasternak

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The pharmacokinetics of aztreonam were studied in 25 adult patients with hematological malignancies. Two groups of 9 patients each received aztreonam (1 or 2 g every 8 h) prophylactically, and 7 infected patients received a therapeutic regimen of aztreonam (1.5 g every 4 h). The mean peak serum concentration after a 1-g dose of aztreonam (given over 0.5 h on day 1) was 75.5 μg/ml; after a 2-g dose it was 177.2 μg/ml. The mean peak serum concentration after a 1.5-g dose of aztreonam (given over 2 h on day 1) was 68.5 μg/ml. The serum half-life ranged between 1.7 and 2.0 h for all regimens studied. The urinary concentration of the metabolite of aztreonam, SQ 26,992, increased during 1 week of administration of the drug; however, serum levels of the metabolite were barely detectable.

Original languageEnglish (US)
Pages (from-to)455-461
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume26
Issue number4
DOIs
StatePublished - 1984

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical pharmacokinetics of aztreonam in cancer patients'. Together they form a unique fingerprint.

Cite this